Fidelity® Select Biotechnology Portfolio

Class No Load (FBIOX)
Scorecard
4 / 5 Stars
Lipper
5 5 3 5 4
Zacks Investment Research
1 (Strong Buy)
Standard & Poor's
5 / 5 Stars
TheStreet.com
A- (Buy)

#2 in Health

U.S. News evaluated 34 Health Funds. Our list highlights the top-rated funds for long-term investors based on the ratings of leading fund industry researchers.

See all Fidelity Investments funds

See full Health rankings

See more fund rankings

Performance

The fund has returned 47.57 percent over the past year, 38.66 percent over the past three years, 29.46 percent over the past five years, and 13.97 percent over the past decade.

Trailing Returns Updated 03.31.2014
Year to date 7.2%
1 Year 47.6%
3 Years (Annualized) 38.7%
5 Years (Annualized) 29.5%
10 Years (Annualized) 14.0%

See more FBIOX performance

Summary

The investment seeks capital appreciation. The fund invests primarily in common stocks. It normally invests at least 80% of assets in securities of companies principally engaged in the research, development, manufacture, and distribution of various biotechnological products, services, and processes and companies that benefit significantly from scientific and technological advances in biotechnology. The fund invests in domestic and foreign issuers. It uses fundamental analysis of factors such as each issuer's financial condition and industry position, as well as market and economic conditions to select investments. The fund is non-diversified.

Fees

Fees are Low compared to funds in the same category.
Fidelity® Select Biotechnology Portfolio has an expense ratio of 0.79 percent.

See more FBIOX fees

Risk

Risk is High compared to funds in the same category according to Morningstar.

See more FBIOX risk

Fund Opinions

The fund's Value Line Overall Rank, a measure of risk-adjusted performance and relative growth in fund returns, is 1 on a scale of 1 to 5, with 1 being the best and 5 the worst.

Value Line 2014-04-10

The fund's Value Line Growth Persistence rank, which awards funds that consistently outperform their broad universes, is 2 for one year, 2 for five years, and 2 for 10 years. Scores are on a 1 to 5 scale, with 1 being the best and 5 the worst.

Value Line 2014-04-10

The fund's Value Line Risk Rank, a measure of volatility, is 5 on a scale of 1 to 5, with 1 being the least volatile and 5 the most.

Value Line 2014-04-10